Summary

Lupus anticoagulants are a heterogeneous group of autoantibodies directed against hemostatically active phospholipids and phospholipid-protein complexes. The presence of lupus anticoagulants can predispose to thrombosis and recurrent abortion. Both arterial and venous thrombosis have been described. Reduced anticoagulant activity of activated protein C has been discussed as a possible pathophysiologic mechanism. Various functional and immunologic tests are available for detecting lupus anticoagulants. The definitive diagnosis of a lupus anticoagulant requires a positive result in two independent functional tests or the simultaneous detection of a lupus anticoagulant in one functional and one immunologic test. Treatment aims at the prevention of thromboembolic complications, so patients should remain on oral anticoagulation until lupus anticoagulant parameters have normalized.

Keywords

Heparin Hexagonal Luminal Thrombocytopenia Prothrombin 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Baker WF, Bick RL (1994) Antiphospholipid antibodies in coronary artery disease: A review. Semin Thromb Haemost 20: 27–45CrossRefGoogle Scholar
  2. 2.
    Bick RL, Ishmail Y, Baker WF (1993) Coagulation abnormalities in precocious artery thrombosis and in patients failing coronary artery bypass grafting and percutaneous transcoronary. Semin Thromb Haemost 10: 412–417CrossRefGoogle Scholar
  3. 3.
    Conley CL, Hartmann R (1952) Hemorrhagic disorder caused by circulating anticoagulant in patients with disseminated lupus erythematosus. J Clin Invest 150: 621–622Google Scholar
  4. 4.
    Dudley DJ, Mitchell MD, Branch DW (1990) Pathophysiology of antiphospholipid antibodies: Absence of prostaglandin-mediated effects on cultured endothelium. Am J Obstet Gynecol 162: 953–959PubMedGoogle Scholar
  5. 5.
    Feinstein DI (1982) Lupus anticoagulant, anticardiolipin antibodies, fetal loss, and systemic lupus erythematosus. Blood 80: 859–862Google Scholar
  6. 6.
    Kornberg A, Silber L, Yona R, Kaufman S (1989) Clinical manifestations and laboratory findings in patients with lupus anticoagulants. Eur J Haematol 42: 90–95PubMedCrossRefGoogle Scholar
  7. 7.
    Mueller JF, Ratnoff O, Heinle RW (1951) Observations on the characteristics of an unusual circulating anticoagulant. Lab Clin Med 38: 254–261Google Scholar
  8. 8.
    Pengo V, Thiagarajan P, Shapiro SS, Heine MJ (1987) Immunological specificity and mechanism of action of IgG lupus anticoagulants. Blood 70: 69–76PubMedGoogle Scholar
  9. 9.
    Pötzsch B, Kawamura H, Preissner KT et al (1992) Thrombophilia in patients with lupus anticoagulant correlates with impaired anticoagulant activity of activated protein C but not with decreased activation of protein C. Blood 80: 267a (Abstract)Google Scholar
  10. 10.
    Pötzsch B, Kawamura H, Preissner KT, Schmidt M, Seelig C, Müller-Berghaus G (1995) Acquired protein C dysfunction but not decreased activity of thrombomodulin is a possible marker of thrombophilia in patients with lupus anticoagulant. J Lab Clin Med 125: 56–65PubMedGoogle Scholar
  11. 11.
    Rauch J, Tannenbaum M, Janoff AS (1989) Distinguishing plasma lupus anticoagulants from anti-factor antibodies using hexagonal ( II) phase phospholipids. Thromb Haemost 62: 892–896PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1997

Authors and Affiliations

  • B. Pötzsch

There are no affiliations available

Personalised recommendations